

Statin Use in Persons with Diabetes (SUPD)

HEDIS Tip Sheet MY 2025



Measure definition	Plans(s)	Quality Program(s)	Collection and Reporting
	Medicare	CMS Star Ratings	Part D prescription claims: • Pharmacy data

Best practices for quality care

- Prescribe at least one statin medication to all members diagnosed with diabetes, regardless of LDL levels.
- Educate members on the importance of statin medications, explaining their role in managing diabetes and reducing heart disease risks.
- Discuss the importance of adherence and address any concerns patients may have about side effects. Ensure they understand how to manage potential side effects and contact you if they experience adverse effects like muscle pain or weakness.
- Review and document all medications and supplements during each patient visit to ensure they align with the patient's needs and minimize unnecessary prescriptions.

Quality score improvement tips

- Instruct pharmacies to process prescriptions through Medicare Part D benefits, especially when utilizing discount programs to ensure cost savings.
- Prescriptions filled with only a discount card will not close the measure gap.
- Submit claims for members that meet exclusion criteria with the appropriate ICD-10 code.
- Write 90-day refills to increase compliance of statins once patients show they tolerate statins and encourage obtaining 90-day supplies through retail or mail-order pharmacies.

Exclusions

- Hospice enrollment.
- End-stage renal disease (ESRD) or dialysis coverage dates.
- Rhabdomyolysis or myopathy.
- Pregnancy, lactation and fertility.
- Cirrhosis.
- Pre-diabetes.
- Polycystic Ovary Syndrome (PCOS).

Note: To exclude patients who cannot tolerate statin medications, submit claims annually using the appropriate ICD-10-CM code (G72.0, M60.80, M60.9, M62.82, and M79.10).

Statin Medications

Description	Prescription
High-intensity statin therapy	• Atorvastatin 40–80 mg
High-intensity statin therapy	• Rosuvastatin 20–40 mg
Moderate-intensity statin therapy	• Atorvastatin 10–20 mg
Moderate-intensity statin therapy	• Rosuvastatin 5–10 mg
Moderate-intensity statin therapy	• Simvastatin 20–40 mg
Moderate-intensity statin therapy	• Pravastatin 40–80 mg
Moderate-intensity statin therapy	• Lovastatin 40 mg
Moderate-intensity statin therapy	• Fluvastatin 40–80 mg
Moderate-intensity statin therapy	• Pitavastatin 1–4 mg
Low-intensity statin therapy	• Simvastatin 10 mg
Low-intensity statin therapy	• Pravastatin 10–20 mg
Low-intensity statin therapy	• Lovastatin 20 mg
Low-intensity statin therapy	• Fluvastatin 20–40 mg

Note: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor medications such as Praluent and Repatha do not satisfy the SUPD measure.

How WellSense can help

HEDIS tip sheets are designed to help WellSense providers improve and report the quality of care delivered to WellSense members across key metrics.

If you have questions around HEDIS documentation and quality measures, please email the Quality Team at WS_Quality_Dept@wellsense.org.